Figures & data
Figure 1. Model for an additional mechanism of action of imatinib mesylate. Imatinib mesylate would contribute to the renewal of the whole bone marrow microenvironment, due to the “normalization” of hematopoietic precursors, able to give rise to healthy bone marrow stromal cells (BMSC), fibroblasts (FB), osteoblasts (OB) and endothelial cells (EC), thus rebuilding the BM “niche.” Normal production of bone morphogenetic proteins (BMP), B lymphocyte activating factor of the tumor necrosis factor family (BAFF) and stromal derived factor-1 (SDF-1) by normal BMSC, FB, EC, would remodel the microenvironment and participate into the development of the B cell population producing tumor-reactive IgM.
